Monday, 18 February

08:00 – 09:30 Davos 2

Session 1: Hypertension Redefined

Chairs:
E. Battegay, Zurich
I. Sudano, Zurich
F. Crea, Rome

08:00 – 08:20

What is a normal blood pressure?

T. F. Lüscher, London
08:20 – 08:40

The new ESC Guidelines on arterial hypertension

G. Mancia, Monza
08:40 – 09:00

Renal denervation revisited

F. Mahfoud, Homburg/Saar
09:00 – 09:20

Hypertension and heart failure

M. A. Pfeffer, Boston
09:20 – 09:30

Panel discussion

09:30 – 10:00

Coffee


10:00 – 11:30 Davos 2

Session 2: Acute Coronary Syndromes ─ A Success Story

Chairs:
T. Moccetti, Lugano
W. Wijns, Galway

10:00 – 10:20

4th Universal definition of MI (the new ESC Guidelines)

A. Lyon, London
10:20 – 10:40

2018 ESC/EACTS Guidelines on myocardial revascularisation

F.-J. Neumann, Bad Krozingen
10:40 – 11:00

"INOCA" and "MINOCA" (Myocardial Infarction and Non-Obtrusive Coronary Arteries): prevalence, prognosis and diagnostic assessment

F. Crea, Rome
11:00 – 11:20

AMIS plus: lessons learned from the Swiss MI registry

H. Rickli, St. Gallen
11:20 – 11:30

Panel discussion

12:00 – 13:15 Seehorn

Update Session Bayer (lunch buffet will be offered)

The horizon of vascular protection and beyond

Chairpersons :
J. E. Deanfield, London
M. Valgimigli, Berne

12:00 – 12:25

The rise of NOACS in stroke prevention for patients with AFib

A. J. Camm, London
12:25 – 12:50

The rationale for combined platelet and coagulation inhibition

P. G. Steg, Paris
12:50 – 13:15

COMPASS: The new direction in vascular protection

S. Yusuf, Hamilton
12:00 – 13:15 Schwarzhorn

Satellite Symposium Amgen (a lunch bag will be offered)

PCSK9 Inhibition: Translation of Fourier into Clinical Practice

Chairperson :
T. F. Lüscher, London

12:00 – 12:05

Introduction

T. F. Lüscher, London
12:05 – 12:25

Genetic evidence for the efficacy of PCSK9 inhibition

A. L. Catapano, Milan
12:25 – 12:45

Familial hypercholesterolemia and PCSK9 mutation in patients with ACS

D. Nanchen, Lausanne
12:45 – 13:05

FOURIER: What does it mean for clinical practice?
Are very low cholesterol levels safe?

F. Mach, Geneva
13:05 – 13:15

Take-home message and closing remarks

T. F. Lüscher, London
13:30 – 15:00 Davos 2

Session 3: Chronic Coronary Syndromes

Chairs:
F.-J. Neumann, Bad Krozingen
S. Windecker, Berne

13:30 – 13:50

Role of revascularisation (PCI) beyond ORBITA: Optimisation of PCI outcomes

W. Wijns, Galway
13:50 – 14:10

PCI vs CABG ─ practical interpretation of the guidelines on myocardial revascularisation

S. Windecker, Berne
14:10 – 14:30

Can biomarkers be utilized to prevent cardiac disease?

A. S. Maisel, San Diego/Basel
14:30 – 14:50

Ischemic heart disease and common mental disorders

E. Battegay, Zurich
14:50 – 15:00

Panel discussion

15:00 – 15:30

Coffee


15:00 – 16:30 Foyer

Poster Session: Arrhythmias, CAD, Platelets & Coagulation

Chair:
G. S. Pitt, New York

15:30 – 16:30 Wisshorn

Meet the Expert Session ─ SCOT Session

Challenging patient cases

Panel:
M. A. Pfeffer, Boston
M. Valgimigli, Berne


Cases:
F. Petracca, Lugano
F. Moccetti, Lucerne
G. Thalmann, Chur


15:30 – 16:30 Seehorn

Meet the Expert Session ─ What is an MI today? The new ESC Definition

Panel and speakers:
L. Räber, Berne
H. Rickli, St. Gallen

15:30 – 16:30 Schwarzhorn

Meet the Expert Session ─ Hypertension

Panel:
F. Mahfoud, Homburg/Saar
G. Mancia, Monza


Cases:
P. Suter, Zurich
I. Sudano, Zurich
T. Dieterle, Liestal


16:30 – 18:00 Davos 2

Session 4: Cardiogenic Shock: the Last Frontier in ACS

Chair:
R. Grocott-Mason, London
F. Nietlispach, Zurich

16:30 – 16:50

Shock ─ the last frontier in ACS management

T. F. Lüscher, London
16:50 – 17:10

Cardiogenic shock: current management and future perspectives

H. Thiele, Leipzig
17:10 – 17:30

Acute heart failure as a cause of cardiogenic shock

L. Lund, Stockholm
17:30 – 17:50

Takotsubo as a cause of cardiogenic shock

C. Templin, Zurich
17:50 – 18:00

Panel discussion

16:30 – 18:00 Davos 1

Session 5: Thrombocardiology

Chairs:
R. Binder, Wels
S. Yusuf, Hamilton

16:30 – 16:50

Update ESC Guidelines on DAPT and practical implementation

M. Valgimigli, Berne
16:50 – 17:10

DAPT or anticoagulation: where is the evidence?

P. G. Steg, Paris
17:10 – 17:30

Role of aspirin in primary prevention

J. H. Beer, Baden
17:30 – 17:50

NOACs in stroke prevention – an update

C. Schmied, Zurich
17:50 – 18:00

Panel discussion

18:00 – 18:15

Dinner Buffet


18:15 – 18:45 Davos 2

Satellite on the Spot Pfizer

How to recognize your cardiac amyloidosis patient

Chair:
A. V. Kristen, Heidelberg

18:00 – 18:10

What is cardiac amyloidosis?

G. Noll, Zurich
18:10 – 18:20

Diagnostic pathway and red flags

S. Stämpfli, Lucerne
18:20 – 18:30

Recognizing & reaching a differential diagnosis of transthyretin cardiac amyloidosis

A. V. Kristen, Heidelberg
19:00 – 20:00 Schwarzhorn

Clinical Decision Seminar ─ Difficult ECG Interpretations

Moderators and Panel:
T. Reichlin, Berne
A. Linka, Winterthur

19:00 – 20:00 Seehorn

Clinical Decision Seminar ─ Echo Pearls / Advanced Echo Imaging

Moderators and Panel:
C. Attenhofer Jost, Zurich
S. Stämpfli, Lucerne
M. Zuber, Zurich

19:00 – 20:00 Wisshorn

Meet the Trialist ─ Odyssey Outcomes and Global Leaders

Odyssey ─ Alirocumab and cardiovascular outcomes after acute coronary syndrome:
C. Müller, Basel
P. G. Steg, Paris


Global Leaders ─ Anti-platelet Therapy After Stent Implantation:
S. Windecker, Berne